Europe Nuclear Imaging Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

The Europe Nuclear Imaging Market is segmented by Product, Application (SPECT Applications and PET Applications), and Geography

Home Market Analysis Healthcare Research Medical Devices Research Medical Imaging Research Diagnostic Imaging Research Europe Nuclear Imaging Solutions Industry

Europe Nuclear Imaging Market Size

CAGR
Study Period 2018 - 2028
Base Year For Estimation 2021
Forecast Data Period 2023 - 2028
Market Size (2023) USD 2.15 Billion
Market Size (2028) USD 2.54 Billion
CAGR (2023 - 2028) 3.34 %

Major Players

Europe Nuclear Imaging Market

*Disclaimer: Major Players sorted in no particular order
setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Europe Nuclear Imaging Market Analysis

The Europe Nuclear Imaging Market size is estimated at USD 2.15 billion in 2023, and is expected to reach USD 2.54 billion by 2028, growing at a CAGR of 3.34% during the forecast period (2023-2028).

The factors that are propelling the growth of the market include technological advancements, increasing diagnostic applications in various diseases, such as cancer and cardiovascular diseases, government support, and a shift from standalone to hybrid modalities. 

Over recent years, scientists, researchers, and technologists have been able to bring systems in clinical practice, in which two or even more than two standalone diagnostic imaging modalities are combined. Some of those multimodality imaging systems include PET/CT, SPECT/CT, PET/MRI, and PET/SPECT/CT. Nuclear medicine is hugely capable of treating cancer and cardiac diseases. Therefore the growing burden of these diseases in the region is boosting the market growth.

Europe Nuclear Imaging Market Trends

This section covers the major market trends shaping the Europe Nuclear Imaging Market according to our research experts:

Oncology is Expected to hold the Highest Market Share in PET Applications

The prevalence of various types of cancer has shown a significant rise over the past two decades. The FDG-PET/CT is more sensitive than a contrast-enhanced CT scan in the staging of several types of lymphoma or in detecting tumor dissemination in several solid cancers, such as breast cancer, lung cancer, and colon cancer. 

According to the World Health Organization, Cancer causes 20% of deaths in the European Region. With more than 3 million new cases and 1.7 million deaths each year, cancer is the most important cause of death and morbidity in Europe. Furthermore, there has been increasing awareness among people in this region about nuclear medicine treatment and diagnosis, which, in turn, has increased the prescriptions by physicians. This is expected to trigger the growth of the market.

europe cancer

Europe Nuclear Imaging Industry Overview

Companies, like Bracco Imaging SpA, Curium, Cardinal Health Inc., Koninklijke Philips NV, GE Healthcare, and Siemens Healthineers, among others, hold a substantial share in the market. Various developments have recently been taking place in the market, such as, in May 2018, Curium enhanced its position in the French PET market with the acquisition of Cyclopharma’s French commercial and manufacturing operations.

Europe Nuclear Imaging Market Leaders

  1. Bracco Imaging SpA

  2. Cardinal Health Inc.

  3. GE Healthcare

  4. Koninklijke Philips NV

  5. Siemens Healthineers

*Disclaimer: Major Players sorted in no particular order

Europe Nuclear Imaging Market.png
Need More Details on Market Players and Competitors?
Download PDF

Europe Nuclear Imaging Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in Prevalence of Cancer and Cardiac Disorders

      2. 4.2.2 Growth in Applications of Nuclear Medicine and Imaging and Rising Technological Advancements

    3. 4.3 Market Restraints

      1. 4.3.1 Regulatory Issues and Lack of Reimbursement

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product

      1. 5.1.1 By Equipment

      2. 5.1.2 By Radioisotope

        1. 5.1.2.1 SPECT Radioisotopes

          1. 5.1.2.1.1 Technetium-99m (TC-99m)

          2. 5.1.2.1.2 Thallium-201 (TI-201)

          3. 5.1.2.1.3 Gallium(Ga-67)

          4. 5.1.2.1.4 Other SPECT Radioisotopes

        2. 5.1.2.2 PET Radioisotopes

          1. 5.1.2.2.1 Fluorine-18 (F-18)

          2. 5.1.2.2.2 Rubidium-82 (RB-82)

          3. 5.1.2.2.3 Other PET Radioisotopes

    2. 5.2 By Application

      1. 5.2.1 SPECT Applications

        1. 5.2.1.1 Cardiology

        2. 5.2.1.2 Neurology

        3. 5.2.1.3 Thyroid

        4. 5.2.1.4 Other SPECT Applications

      2. 5.2.2 PET Applications

        1. 5.2.2.1 Oncology

        2. 5.2.2.2 Cardiology

        3. 5.2.2.3 Neurology

        4. 5.2.2.4 Other PET Applications

    3. 5.3 Geography

      1. 5.3.1 Europe

        1. 5.3.1.1 Germany

        2. 5.3.1.2 United Kingdom

        3. 5.3.1.3 France

        4. 5.3.1.4 Italy

        5. 5.3.1.5 Spain

        6. 5.3.1.6 Rest of Europe

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bracco Imaging SpA

      2. 6.1.2 Cardinal Health Inc.

      3. 6.1.3 GE Healthcare

      4. 6.1.4 Koninklijke Philips NV

      5. 6.1.5 Siemens Healthineers

      6. 6.1.6 NTP Radioisotopes SOC

      7. 6.1.7 Canon Medical Systems Corporation

      8. 6.1.8 Curium

      9. 6.1.9 Nordion Inc.

    2. *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Europe Nuclear Imaging Industry Segmentation

As per the scope of the report, nuclear medicine imaging procedures are non-invasive, with the exception of intravenous injections, and are usually painless medical tests that help physicians diagnose and evaluate medical conditions. These imaging scans use radioactive materials called radiopharmaceuticals or radiotracers. These radiopharmaceuticals are used in diagnosis and therapeutics. They are small substances that contain a radioactive substance that is used in the treatment of cancer, cardiac, and neurological disorders.

Need A Different Region Or Segment?
Customize Now

Europe Nuclear Imaging Market Research FAQs

The Europe Nuclear Imaging Market size is expected to reach USD 2.15 billion in 2023 and grow at a CAGR of 3.34% to reach USD 2.54 billion by 2028.

In 2023, the Europe Nuclear Imaging Market size is expected to reach USD 2.15 billion.

Bracco Imaging SpA, Cardinal Health Inc., GE Healthcare, Koninklijke Philips NV and Siemens Healthineers are the major companies operating in the Europe Nuclear Imaging Market.

Europe Nuclear Imaging Industry Report

Statistics for the 2023 Europe Nuclear Imaging market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Nuclear Imaging analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Europe Nuclear Imaging Equipment Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!